MX2022011287A - Peptidos ciclicos y sus conjugados para el direccionamiento de la integrina alfa-v-beta-6 in vivo. - Google Patents

Peptidos ciclicos y sus conjugados para el direccionamiento de la integrina alfa-v-beta-6 in vivo.

Info

Publication number
MX2022011287A
MX2022011287A MX2022011287A MX2022011287A MX2022011287A MX 2022011287 A MX2022011287 A MX 2022011287A MX 2022011287 A MX2022011287 A MX 2022011287A MX 2022011287 A MX2022011287 A MX 2022011287A MX 2022011287 A MX2022011287 A MX 2022011287A
Authority
MX
Mexico
Prior art keywords
conjugates
integrin
vivo
addressing
beta
Prior art date
Application number
MX2022011287A
Other languages
English (en)
Spanish (es)
Inventor
Johannes Notni
Neil Quigley
Katja Steiger
Original Assignee
Univ Muenchen Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Muenchen Tech filed Critical Univ Muenchen Tech
Publication of MX2022011287A publication Critical patent/MX2022011287A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0052—Small organic molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
    • A61K51/065—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules conjugates with carriers being macromolecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Nuclear Medicine (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
MX2022011287A 2020-03-12 2021-03-12 Peptidos ciclicos y sus conjugados para el direccionamiento de la integrina alfa-v-beta-6 in vivo. MX2022011287A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20162699 2020-03-12
PCT/EP2021/056424 WO2021180969A1 (en) 2020-03-12 2021-03-12 Cyclic peptides and their conjugates for addressing alpha-v-beta-6 integrin in vivo

Publications (1)

Publication Number Publication Date
MX2022011287A true MX2022011287A (es) 2022-12-08

Family

ID=69810651

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022011287A MX2022011287A (es) 2020-03-12 2021-03-12 Peptidos ciclicos y sus conjugados para el direccionamiento de la integrina alfa-v-beta-6 in vivo.

Country Status (11)

Country Link
US (1) US20230173113A1 (https=)
EP (1) EP4117736A1 (https=)
JP (1) JP7787083B2 (https=)
KR (1) KR20220152322A (https=)
CN (1) CN115297893B (https=)
AU (1) AU2021233176A1 (https=)
BR (1) BR112022016986A2 (https=)
CA (1) CA3175061A1 (https=)
IL (1) IL296081A (https=)
MX (1) MX2022011287A (https=)
WO (1) WO2021180969A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021226432A2 (en) * 2020-05-08 2021-11-11 The Regents Of The University Of California Methods of detecting and treating lung damage in respiratory-related viral infections
WO2025218677A1 (zh) * 2024-04-16 2025-10-23 中山医诺维申新药研发有限公司 双重靶向成纤维细胞激活蛋白和整合素亚型的化合物及其制备和应用
WO2026027771A1 (en) 2024-08-02 2026-02-05 Trimt Gmbh Alpha v beta 6-integrin binding cyclopeptides with non-natural amino acids, and conjugates thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19933173A1 (de) 1999-07-15 2001-01-18 Merck Patent Gmbh Cyclische Peptidderivate als Inhibitoren des Integrins alpha¶v¶beta¶6¶
DK2265283T3 (da) 2008-03-18 2014-10-20 Seattle Genetics Inc Auristatin-lægemiddel-linker-konjugater
CA2937753A1 (en) 2014-02-17 2015-08-20 Seattle Genetics, Inc. Hydrophilic antibody-drug conjugates
SI3350222T1 (sl) 2015-09-18 2022-01-31 Technische Universitaet Muenchen Ligandi za integrin avbeta6, sinteza in uporaba le-teh
EP3468984A4 (en) * 2016-06-13 2020-03-11 The Regents of the University of California ALPHA (V) BETA (6) BINDING PEPTIDES AND METHODS OF USE THEREOF
CA3090196A1 (en) 2018-02-06 2019-08-15 Klinikum Rechts Der Isar Der Technischen Universitat Munchen Compound for intraoperative molecular bioimaging, method of making the same, use thereof in intraoperative molecular bioimaging and surgical method comprising intraoperative molecular bioimaging

Also Published As

Publication number Publication date
KR20220152322A (ko) 2022-11-15
JP2023518161A (ja) 2023-04-28
CA3175061A1 (en) 2021-09-16
CN115297893B (zh) 2025-09-23
JP7787083B2 (ja) 2025-12-16
US20230173113A1 (en) 2023-06-08
WO2021180969A1 (en) 2021-09-16
CN115297893A (zh) 2022-11-04
EP4117736A1 (en) 2023-01-18
BR112022016986A2 (pt) 2022-10-25
IL296081A (en) 2022-11-01
AU2021233176A1 (en) 2022-09-08

Similar Documents

Publication Publication Date Title
MX2022011287A (es) Peptidos ciclicos y sus conjugados para el direccionamiento de la integrina alfa-v-beta-6 in vivo.
ECSP10010729A (es) Péptidos dirigidos a crkl
MX2024014691A (es) Enlazadores de conjugacion mejorados
BR112012013502A2 (pt) "polipeptídeos quiméricos e híbridos de fator viii-fc, e métodos de uso dos mesmos".
CY1122155T1 (el) Συζευγμενες ενωσεις που περιλαμβανουν αντισωματα τροποποιημενης κυστεϊνης
PE20251185A1 (es) Proteinas de union condicionalmente activadas restringidas
UY32971A (es) Proteínas de unión al antígeno de la il-23 humana
MX2019008538A (es) Conjugados de superficie celular y composiciones y métodos celulares relacionados.
CY1120522T1 (el) Προσδετες τροποποιημενοι μεσω κυκλικης μεταθεσης ως αγωνιστες και ανταγωνιστες
ATE311464T1 (de) Nk zellen-aktivierende rezeptoren und deren therapeutische und diagnostische verwendungen
GT200600324A (es) Nuevos anticuerpos anti-igf-ir y usos de los mismos
SG10201909675QA (en) Peptide vaccines for cancers expressing tumor-associated antigens
CY1114271T1 (el) Αντισωματα εξουδετερωσης, ανθρωπινου κυτταρομεγαλοϊου και χρηση αυτων
CL2011003333A1 (es) El compuesto n-{1s-[2r-(6,6'-difluoro-3'-{4s-hidroxi-1-[2s-(2s-metilamino-propionilamino)-butiril]-pirrolidin-2r-ilmetil}-1h,1'h-[2,2']biindolil-3-ilmetil)-4s-hidroxi-pirrolidin-1-carbonil]-propil}-2s-metilamino-propionamida; composicion farmaceutica; procedimiento de preparacion; compuestos intermediarios; utiles en el tratamiento de un trastorno proliferativo, tal como cancer, entre otros.
AR073538A1 (es) Anticuerpos multiespecificos que se unen especificamente al receptor del factor de crecimiento epidermico humano 2 (her2) y al factor de crecimiento endotelial vascular (vegf)
PE20110435A1 (es) Composiciones antagonistas del pd-1
UY30324A1 (es) Proteinas de fusion del rage, formulaciones y métodos de uso
CY1121466T1 (el) Αντισωματα εναντι προσδεματων υποδοχεα β1 βραδυκινινης
AR126239A1 (es) Región 5’ no traducida y región 3’ no traducida no naturales y uso de estas
PE20040554A1 (es) Vacunas que comprenden proteinas de fusion
AR050215A1 (es) Metodo para diagnosticar enfermedades utilizando copeptina.
GT200600517A (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
CR8387A (es) Compuestos de pirazolilo e imidazolilo biciclicos y uso de los mismos
CL2024002860A1 (es) Conjugados de fármaco-anticuerpo dirigidos al receptor de folato alfa y métodos de uso
AR124455A2 (es) Proteínas de unión específicas y sus usos